diabetes mellitus
Conditions
Interventions
olmesartan 20mg and azelnidipine 16mg, olmesartan 20mg and trichlormethiazide 1mg for more than 6 weeks each We used HBP data at least 28 days after randomization or switching drugs.
olmesartan 20mg
Sponsors
Kyoto Prefectural University of Medicine, Graduate School of Medical Science
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria were as follows: 40-80 years, type 2 diabetes mellitus, hypertension with the use of RAS inhibitors, RAS inhibitors and CCBs, or RAS inhibitors and diuretics.
Exclusion criteria
Exclusion criteria: Exclusion criteria were as follows: secondary hypertension or malignant hypertension, history of cerebrovascular accident, myocardial infarction or hospitalization for angina pectoris within 6 months before evaluation for study entry, advanced liver or renal dysfunction (serum creatinine equal to or more than 2.0mg/dl or current treatment by dialysis), atrial fibrillation or severe arrhythmia, prescribed 3 and over antihypertensive drugs, prescribed other class of antihypertensive drugs than study drugs (that is, RAS inhibitors, CCBs or diuretics), history of side effects from study drugs, life-threatening condition like malignant tumor or not suited to be a study patients as judged by a physician in charge.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| home blood pressure and home blood pressure variability at least 28 days after randomization or switching drugs. | — |
Countries
Japan
Contacts
Public ContactEmi Ushigome
Kyoto Prefectural University of Medicine, Graduate School of Medical Science Department of Endocrinology and Metabolism
Outcome results
None listed